Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 26, 2015 8:00 PM ET


Company Overview of California Stem Cell, Inc.

Company Overview

California Stem Cell, Inc. discovers, produces, and supplies human cell populations for research, diagnostic, clinical, and therapeutic applications. The company offers stem cell media, such as serum-free media for propagation of human embryonic stem cell (hESC); serum-free media for propagation of human myoblasts; serum-free media formulation to propagate hESC and bias their differentiation to ectodermal lineages; and products for laboratory research purposes. The company also provides human motor neuron progenitors, human cardiac progentior cells, and human neuronal progentior cells for screening and predictive toxicology applications, which are derived from human embryonic stem cells. In ...

5251 California Avenue

Suite 150

Irvine, CA 92617

United States

Founded in 2005



Key Executives for California Stem Cell, Inc.

Chairman of The Scientific Advisory Board, Chief Executive Officer and President
Chief Financial Officer
Age: 44
Chief Medical Officer
Age: 67
Chief Development Officer
Compensation as of Fiscal Year 2014.

California Stem Cell, Inc. Key Developments

Neostem, Inc., California Stem Cell, Inc. - M&A Call

To discuss the definitive agreement to acquire California Stem Cell, Inc

U.S. Food and Drug Administration Approves California Stem Cell, Inc.'s Phase II Cancer Stem Cell Clinical Trial for Ovarian Cancer

California Stem Cell, Inc. announced that the U.S. Food and Drug Administration has approved the company's application to begin a Phase II clinical trial exploring the potential of a patient specific cancer immunotherapy in women with Stage III or IV ovarian, fallopian tube or primary peritoneal cancer. The randomized, double blind study is the company's second cancer therapy approved for clinical trials by the FDA, bolstering its platform approach to treating late stage solid-tumor cancers. The company's patient specific approach to treating metastatic melanoma, recently approved to begin a Phase III trial, provided sufficient safety data to proceed directly to a Phase II study in ovarian cancer. The study design randomizes an estimated 99 adult female patients to two treatment arms. The treatment group will receive Ovapuldencel-T, which is a combination of autologous dendritic cells loaded with irradiated autologous tumor cells in GM-CSF. Ovapuldencel-T is created by first isolating cancer stem cells from the patient's resected tumor sample, then enriching, inactivating and combining these cells with dendritic cells or antigen presenting immune cells which are harvested from the patient's blood. The control group will receive the ‘MC’ treatment, harvested from the patient's blood combined with GM-CSF, granulocyte macrophage colony stimulating factor, a white blood cell growth factor. The trial design calls for both groups to receive subcutaneous injections of their respective treatment weekly for three consecutive weeks, then monthly for the following five months. The trial is expected to last approximately sixty months, including enrollment, treatment, and long term patient follow-up.

California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM

California Stem Cell, Inc. Presents at 9th Annual New York Stem Cell Summit, Feb-18-2014 11:00 AM. Venue: The Convene, Downtown, 32 Old Slip (between Water St. and FDR), New York, NY 10005, United States. Speakers: Hans S. Keirstead, Chairman of the Scientific Advisory Board.

Similar Private Companies By Industry

Company Name Region
Oricula Therapeutics LLC United States
SpeciGen Corp. United States
Adult Stem Cell Corporation of America, Inc. United States
Verdant Therapeutics Inc United States
CARR Separations Inc. United States

Recent Private Companies Transactions

April 14, 2014

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact California Stem Cell, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at